

**How does mild hypothermia affect monoclonal antibody glycosylation?**

Journal:	<i>Biotechnology and Bioengineering</i>
Manuscript ID:	Draft
Wiley - Manuscript type:	Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Sou, Si; Imperial College London, Chemical Engineering Sellick, Christopher; MedImmune, MedImmune Lee, Ken; MedImmune, MedImmune Mason, Alison; MedImmune, MedImmune Kyriakopoulos, Sarantos; Imperial College London, Chemical Engineering Polizzi, Karen; Imperial College London, Life Sciences Kontoravdi, Cleo; Imperial College London, Chemical Engineering
Key Words:	Mild hypothermia, cell metabolism, glycosylation, mAb productivity, glycosyltransferase, flux balance analysis

SCHOLARONE™  
Manuscripts

Review

## How does mild hypothermia affect monoclonal antibody glycosylation?

**Running title: Examining links between cell metabolism and rProtein glycosylation**

Si Nga Sou<sup>1,2,3</sup>, Christopher Sellick<sup>4</sup>, Ken Lee<sup>4</sup>,

Alison Mason<sup>4</sup>, Sarantos Kyriakopoulos<sup>3</sup>, Karen M. Polizzi<sup>1,2</sup>, Cleo Kontoravdi<sup>3\*</sup>

<sup>1</sup>Department of Life Sciences, Imperial College London, London SW7 2AZ, U.K.

<sup>2</sup>Centre for Synthetic Biology and Innovation, Imperial College London, London SW7 2AZ, U.K.

<sup>3</sup>Centre for Process Systems Engineering, Department of Chemical Engineering, Imperial College London, London SW7 2AZ, U.K.

<sup>4</sup>Cell Culture and Fermentation Sciences, MedImmune, Granta Park, Cambridge, CB21 6GH, U.K.

*\* To whom correspondence should be addressed*

Dr Cleo Kontoravdi

Imperial College London

Department of Chemical Engineering

RODH 402

South Kensington, London

SW7 2AZ, UK

Tel: +44 (0)20 7594 6655, Fax: +44 (0)20 7594 6606

Email: [cleo.kontoravdi@imperial.ac.uk](mailto:cleo.kontoravdi@imperial.ac.uk)

## Abstract

The application of mild hypothermic conditions to cell culture is a routine industrial practice used to improve recombinant protein production. However, a thorough understanding of the regulation of dynamic cellular processes at lower temperatures is necessary to enhance bioprocess design and optimisation. In this study, we investigated the impact of mild hypothermia, where Chinese hamster ovary (CHO) cells expressing a mAb were cultured at 36.5°C and with a temperature shift to 32°C during late exponential/early stationary phase, on protein glycosylation. Experimental results showed higher cell viability with decreased metabolic rates. The specific antibody productivity increased by 46.2% at 32°C and was accompanied by a reduction in intracellular nucleotide sugar concentrations and a decreased proportion of the more processed glycan structures on the IgG molecules. To better understand CHO cell metabolism at 32°C, flux balance analysis (FBA) was carried out and constrained with exometabolite data from stationary phase of cultures with or without a temperature shift. Estimated fluxomes suggested reduced fluxes of carbon species towards nucleotide and nucleotide sugar donor synthesis, and more energy was used for product formation. Expression of N-glycosyltransferases that are responsible for N-glycan branching and elongation were significantly lower at 32°C. As a result of mild hypothermia, mAb glycosylation was shown to be affected by both nucleotide sugar donor availability and glycosyltransferase expression. The combined experimental/FBA approach generated a more fundamental view of how product glycosylation can be impacted by changes in culture temperature. Better feeding strategies can therefore be developed based on the understanding of the metabolic flux distribution.

## Keywords

Mild hypothermia, cell metabolism, glycosylation, mAb productivity, glycosyltransferase, flux balance analysis

## Introduction

With positive outcomes from medical treatments, biologics are one of the fastest growing drug groups in the pharmaceutical market, with monoclonal antibodies (mAbs) among the top five best-selling biologics (Aggarwal 2014). In order to increase the specific productivity of recombinant protein ( $q_p$ ), optimisation of industrial bioprocesses continues to be an important focus. The use of biphasic cultures involving a shift in temperature or pH is an approach to increase recombinant protein (rProtein) production yield. For example by reducing culture temperature from 37°C to 33°C, Nam *et al* achieved a nearly 8-fold increase in the specific productivity of recombinant secreted human placental alkaline phosphatase (SEAP) in suspension Chinese hamster ovary (CHO) cell culture (Nam et al. 2008). A shift to mild hypothermic conditions (30°C - 34°C) has therefore become the very frequently employed industrial practice in rProtein production in CHO cell lines (Wulhfard et al. 2008). Not only does mild hypothermia affect rProtein productivity, it also slows down cell metabolism, reduces the rate of nutrient consumption and production of biological waste (Chuppa et al. 1997), causes the partial arrest of the cell population in G0/G1 phase of the cell cycle (Marchant et al. 2008), and stabilises transcriptional species as well as changing the efficiency of protein translation, folding and trafficking (Cain et al. 2013).

With an increasing demand for mAbs, research has led to tailoring of product quantity through mild hypothermia; however few investigations have been made into its effects on the glycosylation of the recombinant products. Regardless of the type of glycoprotein, the sugars attached contribute to protein folding, stability, trafficking, biological activity and serum clearance. In the case of IgG, its Fc-domain controls the activation of downstream immune responses upon binding to Fc $\gamma$  receptors,

1  
2  
3 where the ability of binding and the drug efficacy is influenced by the glycosylation pattern on the  
4 Fc-region. For instance, the absence of core-fucosylation results in the increase in Antibody-  
5 Dependent Cell-Mediated Cytotoxicity (ADCC) activity by approximately 50-fold (Shinkawa et al.  
6  
7  
8  
9  
10 2003), while terminal galactosylation increases Complement-Dependent Cytotoxicity (CDC)  
11 activity of IgG molecules through higher binding affinity of the mAbs to the C1q complement  
12 molecules (Hodoniczky et al. 2005). The final glycan structure of the product is dependent on the  
13 expression levels and the activities of glycosyltransferases, as well as the availability of nucleotide  
14 sugar donors (NSDs), which are substrates of glycosyltransferases during glycan processing. NSD  
15 synthesis is highly influenced by the presence of key nutrients during cell culture (Murrell et al.  
16 2004), e.g. glucose and galactose (Figure 1); as a result changes in cell metabolism during mild  
17 hypothermia can impact the glycosylation of the mAb. To ensure consistency in mAb quality, a  
18 thorough understanding of the relationships among cell metabolism, mAb synthesis and Fc-  
19 glycosylation is necessary.

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32 In this study, we examined the impact of mild hypothermia on an IgG-expressing CHO cell line and  
33 compared culture performance at different temperatures with respect to cell growth, metabolic  
34 profile (nutrients, biological wastes, amino acids and NSDs), mAb synthesis including heavy and  
35 light chain mRNA and assembly intermediates, as well as mAb glycan profiles and  
36 glycosyltransferase expression levels. We then performed flux balance analyses on data sets from  
37 both temperatures in order to generate a better understanding of the intracellular metabolic networks  
38 through calculating differences in metabolic flux changes upon the induction of mild hypothermia.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

## 49 **Material and Methods**

### 50 **Cell line and maintenance**

51  
52  
53 An IgG-producing Chinese hamster ovary CHO-T cell line (MedImmune, Cambridge, UK) was  
54 revived and cultured in CD-CHO medium (Life Technologies, Paisley, U.K.) where 50  $\mu$ M  
55  
56  
57  
58  
59  
60

1  
2  
3 methionine sulfoximine (MSX) was supplemented during the first and second passages only, and  
4  
5 was shaken at 140 rpm in humidified 36.5°C incubator with 5% CO<sub>2</sub> supply. Cells were subcultured  
6  
7 in fresh medium every three days at a seeding density of 3 x 10<sup>5</sup> viable cells/mL. Cell concentration  
8  
9 and cell viability were measured by ViCell® (Beckman Coulter, CA, U.S.A.). Cells were  
10  
11 transferred into the bioreactor system after 3 cell passages.  
12  
13

### 14 **Cell system and Operation**

15  
16 Shake flasks were used in the culture of CHO cells prior to transfer into 1.5 L continuous- stirred  
17  
18 tank DASGIP bioreactors (DASGIP Technology, Juelich, Germany) where each condition was  
19  
20 examined in triplicate bioreactors. Each bioreactor contained an initial culture volume of 0.9 L with  
21  
22 a starting viable cell density of 8 x 10<sup>5</sup> cells/mL. Within the 14-day cell culture period, the cultures  
23  
24 were maintained at pH 6.9±0.1 at 36.5°C, or with a temperature shift to 32°C on day 6 post  
25  
26 inoculation, with a stirring speed at 150 rpm and CO<sub>2</sub> air concentration at 5% v/v. On days 2, 4, 6,  
27  
28 8, 10 and 12 of the culture period, the cultures were supplemented with 10% by volume CD  
29  
30 EfficientFeed™ C AGT™ Nutrient supplement (Life Technologies, Paisley, U.K.) and 5 mL  
31  
32 additions of 15% antifoam C (Sigma-Aldrich, Dorset, U.K.) were added when excessive foaming  
33  
34 occurred.  
35  
36  
37

### 38 **Analytical assays**

39  
40 To determine the amount of intracellular metabolite, heavy and light chain mRNA and polypeptides  
41  
42 that were produced throughout the experiments, 5 x 10<sup>6</sup> cells were collected for DNA/RNA  
43  
44 quantification and 2 x 10<sup>6</sup> cells each for HC/LC mRNA, polypeptide and NSD analyses. Cells were  
45  
46 centrifuged at 200 rpm for 5 minutes in an Eppendorf microfuge, cell pellets were washed twice  
47  
48 with PBS. Clarified supernatants were used to determine extracellular nutrient and secreted mAb  
49  
50 concentrations. Both pellets and supernatant samples were stored at -80°C.  
51  
52  
53

### 54 **(a) Nutrients, metabolites and secreted mAb concentrations**

1  
2  
3 Extracellular concentrations of glucose, lactate and ammonia in supernatant samples were  
4 determined using the YSI Bioprofiler 800 (NOVA Biomedical, MA, U.S.A.). Extracellular amino  
5 acid quantification was performed with a Waters Acquity ultra-performance liquid chromatography  
6 (UPLC, Waters, Hertfordshire, U.K.) using the AccQ-tag kit according to the manufacturer's  
7 instructions. Secreted mAb titre was determined using a Protein-A affinity chromatography method.  
8  
9

#### 14 **(b) DNA and RNA extraction and cDNA preparation**

16 The total DNA and RNA of each sample was extracted from cell pellets using the All prep  
17 DNA/RNA mini purification kit (Qiagen, Manchester, U.K.) as described in the manufacturer's  
18 instructions. 300 ng of extracted RNA from each sample was reversed transcribed into cDNA using  
19 1  $\mu\text{L}$  of the RT Primer Mix of the QuantiTect Reverse Transcription Kit (Qiagen, Manchester,  
20 U.K.).  
21  
22  
23  
24  
25  
26

#### 27 **(c) mAb heavy and light chain, glycosyltransferase mRNA measurement**

29 mRNA expression levels of mAb heavy (HC HuG1) and light chains (LC HuKappa) in each sample  
30 were quantified by quantitative real-time polymerase chain reaction (qRT-PCR). Each sample was  
31 analysed in triplicate PCR reactions. A total of 10  $\mu\text{L}$  of reaction volume was used per sample in a  
32 96 well-plate, with 5  $\mu\text{L}$  of 2x SYBR Green Supermix (Sigma-Aldrich, Dorset, U.K.), 0.64  $\mu\text{L}$  of  
33 cDNA and 500 nM of each primer. Non-template controls were carried out for each PCR reaction.  
34 PCR reactions were initiated with 3 min at 95 °C for SYBR Green activation; followed by 40 cycles  
35 of 95°C for 30 s, 60°C for 75 s and 72°C for 30 s. The product integrity was verified by the DNA  
36 melting curve from 65°C to 95°C (read every 0.3°C). Results were compared to the  $C_t$ -number of a  
37 house-keeping  $\beta$ -actin gene for relative analysis. Primer sequences are available on request.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

#### 50 **(d) Determination of heavy and light chain mRNA half-lives**

52 To estimate the stability of heavy and light chain mRNA molecules, duplicate shake flask  
53 experiments were performed at both 36.5°C and 32°C. At late exponential phase (day 6) of each  
54 culture, 65  $\mu\text{M}$  of the transcription inhibitor DRB (5,6 dichloro-1  $\beta$ -D-ribofuranosyl  
55  
56  
57  
58  
59  
60

1  
2  
3 benzinimidazole, Sigma-Aldrich, Dorset, U.K.) dissolved in 100% ethanol (VWR, Lutterworth,  
4 U.K.) was added to block cell transcription. The same volume of ethanol was added to the control  
5 cultures at both temperatures to compensate for the effect of ethanol on the cells.  $5 \times 10^6$  cells/mL  
6 were collected from each culture at 0, 3, 6, 9, 12 hours after the inhibitor/ethanol additions.  
7 Transcribed cDNA from each sample were quantified by qRT-PCR. Results were normalized to a  
8 standard curve generated with known amounts of the HC/LC plasmids and their respective  $C_t$ -  
9 values. mRNA levels were determined from their respective standard curves and decay rates were  
10 calculated.

#### 20 (e) Intracellular mAb polypeptides and assembly intermediate analysis

21 Cell pellets with  $2 \times 10^6$  viable cells were washed with PBS at 4°C to remove any supernatant  
22 residue. The PBS was aspirated and cell pellets were resuspended in 125  $\mu$ L of CellLytic™ M  
23 solution (Sigma-Aldrich, Dorset, U.K.) supplemented with 1% (v/v) protease inhibitor cocktail  
24 (Sigma-Aldrich, Dorset, U.K.). Mixtures were incubated at room temperature on an orbital shaker  
25 for 15 min. The lysates were spun at 18,000 x g for 15 min. The protein-containing supernatant was  
26 stored at -80°C prior to Western blot analysis. 4  $\mu$ L of 4x NuPAGE sample buffer was added to 12  
27  $\mu$ L of each sample and 100, 10, 1 and 0.1  $\mu$ g of purified IgG controls (provided by MedImmune,  
28 Granta Park, Cambridge, U.K.). Each sample was run on 12% Precast Protein gel (Thermo  
29 Scientific, Horsham, U.K.) in Tris-HEPES running buffer at 120 V for 1 h. The polyacrylamide gel  
30 was washed twice with dH<sub>2</sub>O before being transferred in a semi-dry transfer system (Bio-Rad,  
31 Hertfordshire, U.K.) onto a methanol-activated PVDF transfer membrane (Millipore, Watford,  
32 U.K.) at 0.3 A for 50 min. After successful transfer, 1:1000 horseradish peroxidase (HRP)-  
33 conjugated goat anti-human IgG Fc primary antibody (Jackson Immunoresearch, PA, U.S.A.) was  
34 used as the primary antibody and visualisation proceeded with the WesternBreeze®  
35 Chemiluminescent Anti-Goat-Kit (Life Technologies, Paisley, U.K.) according to the  
36 manufacturer's instructions and using a 10 min exposure time (FujiFilm, Bedford, U.K.). The  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 intensity of each band was quantified using MYImageAnalysis Software Manual (Thermo  
4 Scientific, Horsham, U.K.) and concentrations were determined through comparison to the IgG  
5 protein standard.  
6  
7

8  
9  
10 **(f) Analysis of galactosyltransferase III (GalTIII) protein expression**

11  
12  $2 \times 10^6$  viable cell pellets were rinsed with 4°C PBS prior to cell lysis in 200 µL of M-PER  
13 Mammalian protein extraction reagent (Thermo Scientific, Horsham, U.K.) supplemented with 1%  
14 (v/v) protease inhibitor cocktail (Sigma-Aldrich, Dorset, U.K.). Samples were gently shaken for 10  
15 min before they were sonicated at 3 bursts of 5 seconds on ice, with 25 seconds intervals and an  
16 amplitude power of 20. Cell debris was removed by centrifugation at 14,000 x g for 15 min.  
17  
18 Membrane protein-containing supernatant was stored at -80°C prior to Western blot analysis as  
19 described in (e), with an exception of 10 min 100°C sample incubation before gel electrophoresis.  
20  
21  $\beta$ -1,4-Gal-T3 Antibody (N20) (Santa Cruz Biotechnology, Texas, USA) was used as primary  
22 antibody for western blotting and protein concentration in each sample was compared to known  
23 concentrations of  $\beta$ -1,4-Gal-T3 (N20) blocking peptide (Santa Cruz Biotechnology, Texas, USA).  
24  
25  
26  
27

28  
29  
30 **(g) Extraction of intracellular NSD and analysis**

31  
32 Intracellular nucleotide sugars were extracted by an acetonitrile extraction method (Dietmair et al.  
33 2010; Viant et al. 2005). In brief, 400 µL of ice cold 50% v/v aqueous acetonitrile was added to a  
34 cell pellet containing  $2 \times 10^6$  cells. The mixture was incubated on ice for 10 min before  
35 centrifugation at 18,000 x g for 5 min at 0°C. Supernatant was dried thoroughly using a SpeedVac  
36 (Savant Inc. Laboratory, MI, U.S.A.). Dried samples were resuspended in 150 µL of deionised  
37 water and were filtered by 0.2-µm syringe filter units (Fisher Scientific, Loughborough, U.K.)  
38 before HPAEC analysis. The NSD analytic method was based on del Val et al. (2013), using a  
39 CarboPac PA-1 column with a PA-1 guard column (Dionex, CA, USA). Elution of samples was  
40 done using a gradient of E1 (3 mM NaOH) and E2 (1.5 mM sodium acetate in 3 mM NaOH)  
41 buffers as mobile phases. Detection of all species was carried out at two absorbance wavelengths:  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 271.6 nm for all cysteine-bearing species and 262.1 nm for the rest of all other compounds. This  
4  
5 method was capable to resolve 10 nucleotides - ATP, CTP, GTP, UTP, AMP, ADP, CMP, GMP,  
6  
7 UMP and UDP, as well as 9 nucleotide sugar compounds o CMP-Neu5Ac, UDP-GalNAc, UDP-  
8  
9 GlcNAc, UDP-Gal, UDP-Glc, GDP-Fuc, GDP-Man, GDP-Glc and UDP-GlcA.

#### 10 11 **(h) mAb glycan analysis**

12  
13 Purified mAb samples with concentration range of 1.25 - 7.5 mg/mL were prepared for glycan  
14  
15 analysis using the ProfilerPro Glycan Profiling Kit (PerkinElmer, MA, U.S.A.). 8  $\mu$ L of samples  
16  
17 were firstly denatured in the Denaturing Plate containing 3  $\mu$ L of denaturing solution for 10 min at  
18  
19 70°C. 11  $\mu$ L of denatured materials were next transferred to Peptide-N-Glycosidase F (PNGase F)  
20  
21 Plate and was incubated at 37°C for 1 h to separate glycan from the protein. 8  $\mu$ L of the digested  
22  
23 samples were transferred to the Labelling Plate and was incubated at 55°C for 2 h for glycan  
24  
25 labelling. Dried samples were reconstituted in 100  $\mu$ L of molecular grade water and glycan analysis  
26  
27 was performed by the LabChip® GXII instrument (PerkinElmer, MA, U.S.A.).  
28  
29  
30  
31

#### 32 33 **Flux balance analysis (FBA)**

34  
35 The R workspace (R Development Core Team 2010) and the Sybil package (Gelius-Dietrich et al.  
36  
37 2013) were used to perform the FBA. The metabolic network was constructed by Kyriakopoulos  
38  
39 and Kontoravdi (2014) based on the network proposed by Carinhas et al. (2013). The biomass  
40  
41 composition used was that proposed by Selvarasu et al. (2012) for CHO cells, but excluding Cys.  
42  
43 The final model consisted of 120 metabolites, 97 intracellular reactions and 57 transport equations,  
44  
45 as shown in the Supplementary Table 2. The model was optimised by assuming maximum biomass  
46  
47 and IgG accumulation during exponential phase, and maximum IgG accumulation at stationary  
48  
49 phase. FBA was conducted based on the experimentally measured concentrations of extracellular  
50  
51 amino acids, glucose, lactate, ammonia and viable cell density and IgG titres. The upper and lower  
52  
53 limits were set within 1 standard deviation while the remaining extracellular fluxes were set at  
54  
55  $\pm 20\%$  (Carinhas et al. 2013). Choline was included in the network to account for lipid synthesis. In  
56  
57  
58  
59  
60

1  
2  
3 order to examine the glucose fluxes to nucleotide and NSD production for glycosylation, GlcNAc,  
4 GalNAc, Mann, Fuc, Gal and Neu5Gc were added in the biomass equation. The amount of each  
5 NSD necessary for host cell protein glycosylation, was estimated based on the results from the MS  
6 glycan study in Stanley (2010), as well as the occurring frequency of N- and O-linked glycans  
7 based on Apweiler et al. (1999). These data were then used to calculate the respective  
8 stoichiometric coefficients (mmol per gram of dry cell weight, mmol/gDCW) that were  
9 incorporated in the biomass equation and used in the FBA analysis.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

## 20 Results

### 21 CHO cell culture behaviour and mAb production profile during mild hypothermia

22 Two sets of experiments were carried out to investigate the impact of mild hypothermia: 14-day  
23 CHO cell fed-batch culture at 36.5°C or with a temperature shift from 36.5°C to 32°C on day 6 at  
24 late exponential phase. Figures 2A and B show the growth profiles of CHO cell cultures and their  
25 specific mAb productivities at both temperatures. When compared to culture at 36.5°C, cells that  
26 were temperature-shifted to 32°C maintained a high viability of 98.2% on harvest day with only a  
27 10.0% reduction in their integral viable cell concentration (IVCC). Accompanied with increased  
28 cell viability, a 46.2% rise in the specific mAb productivity was observed. To better elucidate the  
29 increase in  $q_{\text{mAb}}$  at lower temperature, intracellular species produced in the mAb synthesis process  
30 were experimentally quantified. Results show that only the heavy chain mRNA expression level  
31 was higher at 32°C (Figures 3A and B), while at a translational level the overall concentrations of  
32  $H_2$  and  $H_2L$  mAb assembly intermediates increased upon temperature shift (Figures 3C and D). In  
33 both mRNA and polypeptide concentrations, our results suggest the heavy chain to be the rate-  
34 determining species for mAb synthesis, with the increase in HC mRNA transcripts at 32°C being  
35 advantageous for overall mAb production (Figure 3E). This is in good agreement with findings of  
36 O'Callaghan et al. (2010) where they concluded that  $q_{\text{mAb}}$  was controlled mostly by the rate of HC  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 translation. In addition, a lower culture temperature was shown to stabilise both HC and LC mRNA,  
4  
5 with 14% and 22% reductions in HC and LC mRNA decay rates (Table 1), respectively.  
6  
7

### 8 **The impact of mild hypothermia on nucleotide sugar donor synthesis and mAb glycosylation**

9  
10 To ensure product quality, the final secreted mAb Fc-glycan profile was analysed on days 8, 10, 12  
11  
12 and 14 for both temperatures. With respect to time, the terminal glycan structures observed in  
13  
14 harvest products were comparable to those on days 8, 10 and 12. With mild hypothermia, alongside  
15  
16 with the increased in mAb protein titre, we observed a significant increase in the proportion of IgG  
17  
18 molecules with underprocessed glycan structures, approximately 3% and 17% increase in G0 and  
19  
20 G0F, respectively and also 15% and 3% reduction in the fraction of the more processed glycoforms  
21  
22 namely G1F and G2F, respectively on day 12 (Figure 4A).  
23

24  
25 Murrell et al. (2004) demonstrated the complexity of the intracellular NSD synthetic pathway,  
26  
27 where the type of sugar source (glucose, galactose, mannose etc.) and their uptake rate affected the  
28  
29 production of nucleotide sugars, the building components for protein glycosylation. The availability  
30  
31 of glutamine in the system was also critical for nucleotide synthesis. Quantification of the  
32  
33 intracellular NSD concentrations was therefore a useful approach to understand the relationship  
34  
35 between CHO cell metabolism and product glycosylation. UDP-Glc is essential in the initiation of  
36  
37 N-linked glycosylation due to its role in dolichol-linked precursor oligosaccharide  
38  
39 (GlcNAc<sub>2</sub>Man<sub>9</sub>Glc<sub>3</sub>) generation in the ER lumen. The intracellular concentration of UDP-Glc  
40  
41 remained similar at exponential phases. However, in part due to reduced consumption of glucose  
42  
43 during mild hypothermia, the amounts of UDP-Glc, UDP-Gal and UDP-GlcNAc (essential for  
44  
45 glycan branching and elongation) within the cells decreased upon temperature shift (Figures 4 B-D).  
46  
47  
48

### 49 **Impact of mild hypothermia on expression of genes related to N-glycosylation**

50  
51 From the glycan analysis we observed an increase in the underprocessed glycan structures in the  
52  
53 secreted mAb produced at 32°C. In addition to cell metabolic adjustments induced by mild  
54  
55 hypothermia where it affected the availability of key NSDs for mature glycoform formation,  
56  
57  
58  
59  
60

1  
2  
3 expression of proteins that are involved in N-linked glycosylation could be temperature sensitive.  
4  
5 Thus, we investigated the mRNA expression levels of 6 NSD glycosyltransferase enzymes, namely  
6  
7 2 N-acetylglucosaminyltransferases (GnTI and GnTII) which are involved in glycan branching, 3  
8  
9 galactosyltransferases ( $\beta$ -GalTI, II and III) and fucosyltransferase (FucT) that adds GDP-Fuc onto  
10  
11 the N-glycan core in IgG. In addition, we examined the mRNA expression levels of 2 transporters:  
12  
13 UDP-Gal and UDP-GlcNAc transporters, responsible for exchanges of their respective NSDs  
14  
15 between the Golgi apparatus and the cell cytosol. Figure 5A describes the transcript expression  
16  
17 profiles at both temperatures. The glycosyltransferases GnTII, GalTI, GalTIII, and FucT showed  
18  
19 significantly lower mRNA expression levels at 32°C. Overall, GnTI, GalTII and the two  
20  
21 transporters examined did not show significant variation in their expression levels, apart from a  
22  
23 drop in mRNA level of UDP-GlcNAc T at day 14 of the mild hypothermic cultures. The  
24  
25 downregulation of GalTIII gene expression observed at 32°C was further supported by the  
26  
27 reduction in  $\beta$ -1,4-GalT-III protein expression in cells cultured in mild hypothermic condition  
28  
29 (Figure 5B).  
30  
31  
32  
33

### 34 **The impact of mild hypothermia on CHO cell metabolism through flux balance analysis and** 35 **experimental studies** 36 37

38  
39 Prompted by the reduction in NSD availability observed at 32°C, flux balance analysis (FBA) was  
40  
41 applied to understand how lower culture temperature impacted on CHO cell metabolism. Prior to  
42  
43 performing the FBA, the consumption and production rates of each exometabolite measured were  
44  
45 calculated with the rate calculation code of (Kyriakopoulos 2014). Table 2 shows the calculated  
46  
47 production and consumption rates of each exometabolite during the two phases at both  
48  
49 temperatures. The overall amino acid and glucose exchanges from the extracellular environment  
50  
51 were higher at exponential than at stationary phase. By comparing the two temperatures at  
52  
53 stationary phase, we can see there was a reduction in the consumption rates of metabolites at 32°C,  
54  
55 together with a shift from lactate production to consumption which correlated well with  
56  
57  
58  
59  
60

1  
2  
3 experimental data. The rate of IgG production was also higher at 32°C. The FBA was then  
4  
5 constrained with the rates of exometabolites, maximum  $q_{\text{mab}}$  and growth rate ( $\mu$ ) during exponential  
6  
7 (days 3-6) growth, but maximum  $q_{\text{mab}}$  and exometabolite uptake/production rates only at late  
8  
9 exponential/stationary phase (days 7-10). Results from the FBA (Figure 6) showed that during  
10  
11 exponential growth the flux of glucose entering the TCA cycle through glycolysis was less than that  
12  
13 during stationary phase, when there was increased storage of carbon as glycogen and higher fluxes  
14  
15 out from the TCA into biomass, IgG, amino acid and energy generations to sustain cell growth at  
16  
17 exponential growth. At 36.5°C, the flux of glucose from glycolysis to the TCA during stationary  
18  
19 phase increased and the TCA cycle was more efficient, with reduced flow of species toward  
20  
21 biomass/IgG production. However, when mild hypothermia was induced, lactate became the main  
22  
23 fuel for the TCA cycle, with no carbon loss to glycogen production. This metabolic shift from  
24  
25 glucose to lactate was supported by the dramatic drop of extracellular lactate concentration  
26  
27 observed experimentally (Figure 7B).  
28  
29  
30  
31

32 While most of the product generated from glycolysis was consumed within the TCA cycle at  
33  
34 36.5°C, at 32°C less energy was spent on the TCA cycle, the consumption of glutamate was higher,  
35  
36 where glutamate fluxes towards glutamine and aspartate syntheses increased with mild  
37  
38 hypothermia, which contributed to the increase in IgG production. Moreover, the conversion rate  
39  
40 from glucose-6-phosphate into ribulose-5phosphate (R5P) and NADPH was 21 times lower at  
41  
42 32°C. This contributed to reduced synthetic rates of nucleotide, NSD and lipids. Supplementary  
43  
44 Table 3 illustrates the lower fluxes of carbon and energy sources entering into all the three synthetic  
45  
46 pathways at 32°C, accompanied by increase production of glutamine and a high exchange rate of  
47  
48 glutamine from the cell cytosol to the extracellular environment. In addition, the synthesis of  
49  
50 hexosamines (GlcNAc, GalNAc) requires glutamine and a reduced flux of glutamine into  
51  
52 nucleotide/NSD synthesis was suggested by the FBA, which caused the drop of UDP-GlcNAc  
53  
54 concentration that was measured experimentally.  
55  
56  
57  
58  
59  
60

1  
2  
3 Through experiments, CHO cells were shown to be metabolically less active when the temperature  
4  
5 was lowered to 32°C at late exponential phase. Glucose was the main carbon source in the cultures  
6  
7 and at 32°C we observed a reduction in glucose consumption, reflected by the higher extracellular  
8  
9 glucose concentration in Figure 7A. This coincided with the estimation from the FBA where less  
10  
11 glucose entered into glycolysis. On the other hand, cells achieved an increase in extracellular  
12  
13 ammonia level upon temperature shift (days 6-10) but it levelled out with the concentration  
14  
15 obtained at 36.5°C on day 10, when most NH<sub>4</sub> was consumed to generate glutamine (Figure 7C).  
16  
17  
18  
19  
20  
21

## 22 Discussion

23  
24 The adaptations that CHO cells undergo in response to mild hypothermia have led to significant  
25  
26 changes in the productivity and the glycoform composition of the mAb. The prolonged cell viability  
27  
28 that we observed in this study could be explained by the work of Marchant et al. (2008) which  
29  
30 demonstrated that cells experienced a partial cell cycle arrest upon mild hypothermia. Instead of  
31  
32 dividing cells for high cell density, more energy was generated within the TCA to sustain other  
33  
34 intracellular activities, such as mAb protein synthesis and trafficking.  
35  
36

37  
38 As expected, at exponential growth, higher proportions of energy and amino acids were consumed  
39  
40 for biomass formation, while reduced consumption towards cell growth was observed at stationary  
41  
42 phase. During mild hypothermia, there was an increased net flux of amino acids into IgG protein  
43  
44 synthesis, which was illustrated by a 46.2% rise in the rate of mAb production. As a result of slower  
45  
46 cell metabolism, more energy is likely to have been channelled towards protein production, which  
47  
48 could have consequently led to reduced inputs towards protein glycosylation.  
49  
50

51  
52 In addition, the reduced consumption of glucose that was experimentally observed was mirrored by  
53  
54 a lowered influx of extracellular glucose into glycolysis shown in our FBA, where a metabolic shift  
55  
56 to lactate consumption was triggered by the reduced production of NADH. This was to maintain the  
57  
58 TCA cycle efficiency during stationary phase. However, the synthesis of nucleotides and nucleotide  
59  
60



1  
2  
3 sugars relied on the availability of glucose and glycolysis species namely glucose-6-phosphate and  
4  
5 fructose-6-phosphate, together with R5P generated from the pentose-phosphate pathway, which is  
6  
7 fuelled from glycolysis. The reduced metabolic rates in these pathways resulted in lower synthetic  
8  
9 rates of the glycosylation substrates. Since the transcript expression of GnTIII, GalTs and FucT were  
10  
11 shown to be lower under mild hypothermia, accompanied by reduced GalT protein expression at  
12  
13 32°C, decrease in NSD synthesis, UDP-GlcNAc and UDP-Gal in particular, together with lower  
14  
15 glycosyltransferase expression levels restrict the formation of bi-antennary and more complicated  
16  
17 glycan profiles which require terminal galactosylation.  
18  
19

20  
21 In addition, lipid synthesis relies on availability of G6P, AcCoA and various amino acids. The  
22  
23 decrease in lipid synthesis calculated by the FBA could affect the generation of cell membranes and  
24  
25 transport vesicles, which are important in the embedment for nucleotide-sugar transporters into the  
26  
27 lipid bilayers.  
28

29  
30 By combining experimental data with the FBA approach, we managed to draw a relationship among  
31  
32 the increase in mAb synthesis, the deceleration in cell metabolism and reduced maturation of mAb  
33  
34 glycan structures during mild hypothermia. Figure 8 provides an overview of how mAb  
35  
36 glycosylation can be influenced by lowering culture temperature. The low metabolic state of cells  
37  
38 reduced NSD synthesis as well as glycosyltransferase expression, GalT in particular, which directly  
39  
40 impacted on the process of protein glycosylation. Under mild hypothermic condition, a higher  
41  
42 proportion of energy and amino acid consumptions were used for product formation than NSD  
43  
44 synthesis. By exploring this relationship, it may be possible to predict changes in glycan structure  
45  
46 based on the effects of different bioprocess conditions on cell metabolism, as well as developing  
47  
48 improved feeding strategies to target specific glycan patterns.  
49  
50

### 51 52 53 **Concluding remarks**

54  
55 This study explored the impact of mild hypothermia on mAb N-glycosylation, by examining  
56  
57 changes in cell metabolism and IgG synthesis experimentally and computationally through flux  
58  
59  
60



1  
2  
3 balance analysis. We observed a slow-down in cell metabolism but an increase in recombinant IgG  
4  
5 production when mild hypothermia was induced at stationary phase. The product quality, however,  
6  
7 was influenced by culture temperature, with a higher fraction of the under-processed glycan  
8  
9 structures found in the secreted IgG produced at 32°C. The relationship among a reduced cell  
10  
11 metabolic rate, an increased IgG titre and the variation in product glycosylation was better  
12  
13 established through the use of the FBA. Estimated fluxomes revealed an overall lower cell  
14  
15 metabolism at 32°C during stationary phase, together with decreased fluxes of carbon, energy and  
16  
17 glutamine into nucleotide and NSD synthesis. More energy and metabolites were also estimated to  
18  
19 contribute to a higher mAb productivity (Yoon et al. 2006), which further restricted resources that  
20  
21 were necessary for mAb glycosylation. Furthermore, expression levels of key enzymes for N-linked  
22  
23 glycan branching and elongation was downregulated, this in part contributed to the generation of  
24  
25 pre-matured glycan structures in the secreted product. Our study allowed better clarification on the  
26  
27 behaviours of CHO cells in mild hypothermia and demonstrated its impact on mAb Fc-  
28  
29 glycosylation, which will be beneficial for future design of experiment.  
30  
31  
32  
33  
34

### 35 Acknowledgement

36  
37 SNS thankfully acknowledges the Biotechnology and Biological Sciences Research Council and  
38  
39 Bioprocessing Research Industry Club for her studentship. The financial contribution of MedImmune  
40  
41 plc is gratefully acknowledged. The authors thank Kalpana Nayyar, Andrew Smith and Neil Birkett  
42  
43 for their assistance in glycan, mAb titre analyses and mAb purification, respectively. KMP and CK  
44  
45 thank Research Councils U.K. for their fellowships. CK thanks Lonza Biologics for their financial  
46  
47 support.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

- Aggarwal S. 2014. What's fueling the biotech engine[mdash]2012 to 2013. *Nat Biotech* 32(1):32-39.
- Apweiler R, Hermjakob H, Sharon N. 1999. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. *Biochim Biophys Acta* 1473(1):4-8.
- Cain K, Peters S, Hailu H, Sweeney B, Stephens P, Heads J, Sarkar K, Ventom A, Page C, Dickson A. 2013. A CHO cell line engineered to express XBP1 and ERO1-Lalpha has increased levels of transient protein expression. *Biotechnol Prog* 29(3):697-706.
- Carinhas N, Duarte TM, Barreiro LC, Carrondo MJ, Alves PM, Teixeira AP. 2013. Metabolic signatures of GS-CHO cell clones associated with butyrate treatment and culture phase transition. *Biotechnology and Bioengineering* 110(12):3244-57.
- Chuppa S, Tsai YS, Yoon S, Shackelford S, Rozales C, Bhat R, Tsay G, Matanguihan C, Konstantinov K, Naveh D. 1997. Fermentor temperature as a tool for control of high-density perfusion cultures of mammalian cells. *Biotechnol Bioeng* 55(2):328-38.
- del Val IJ, Kyriakopoulos S, Polizzi KM, Kontoravdi C. 2013. An optimized method for extraction and quantification of nucleotides and nucleotide sugars from mammalian cells. *Anal Biochem* 443(2):172-80.
- Dietmair S, Timmins NE, Gray PP, Nielsen LK, Kroemer JO. 2010. Towards quantitative metabolomics of mammalian cells: Development of a metabolite extraction protocol. *Analytical Biochemistry* 404(2):155-164.
- Gelius-Dietrich G, Desouki AA, Fritzeimer CJ, Lercher MJ. 2013. sybil - Efficient constraint-based modelling in R. *BMC Syst Biol* 7(1):125.
- Hodoniczky J, Zheng YZ, James DC. 2005. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. *Biotechnol Prog* 21(6):1644-52.
- Kyriakopoulos S. 2014. Amino acid metabolism in Chinese hamster ovary cell culture. London, U.K.: Imperial College London.
- Kyriakopoulos S, Kontoravdi C. 2014. A framework for the systematic design of fed-batch strategies in mammalian cell culture. *Biotechnol Bioeng*.
- Marchant RJ, Al-Fageeh MB, Underhill MF, Racher AJ, Smales CM. 2008. Metabolic rates, growth phase, and mRNA levels influence cell-specific antibody production levels from in vitro-cultured mammalian cells at sub-physiological temperatures. *Molecular biotechnology* 39(1):69-77.
- Murrell MP, Yarema KJ, Levchenko A. 2004. The systems biology of glycosylation. *Chembiochem* 5(10):1334-47.
- Nam JH, Zhang F, Ermonval M, Linhardt RJ, Sharfstein ST. 2008. The effects of culture conditions on the glycosylation of secreted human placental alkaline phosphatase produced in Chinese hamster ovary cells. *Biotechnol Bioeng* 100(6):1178-92.
- O'Callaghan PM, McLeod J, Pybus LP, Lovelady CS, Wilkinson SJ, Racher AJ, Porter A, James DC. 2010. Cell line-specific control of recombinant monoclonal antibody production by CHO cells. *Biotechnol Bioeng* 106(6):938-51.
- R Development Core Team. 2010. R: A language and environment for statistical computing. Austria.
- Selvarasu S, Ho YS, Chong WPK, Wong NSC, Yusufi FNK, Lee YY, Yap MGS, Lee DY. 2012. Combined in silico modeling and metabolomics analysis to characterize fed-batch CHO cell culture. *Biotechnology and Bioengineering* 109(6):1415-1429.
- Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M and others. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. *J Biol Chem* 278(5):3466-73.
- Stanley P. 2010. Structural data for the community on the popular CHO mutant cell lines. *Functional Glycomics Gateway*.

- 1  
2  
3 Viant M, Bundy J, Pincetich C, de Ropp J, Tjeerdema R. 2005. NMR-derived developmental metabolic  
4 trajectories: an approach for visualizing the toxic actions of trichloroethylene during  
5 embryogenesis. *Metabolomics* 1(2):149-158.
- 6 Wulhfard S, Tissot S, Bouchet S, Cevey J, De Jesus M, Hacker DL, Wurm FM. 2008. Mild hypothermia  
7 improves transient gene expression yields several fold in chinese hamster ovary cells.  
8 *Biotechnology Progress* 24(2):458-465.
- 9 Yoon SK, Kim SH, Song JY, Lee GM. 2006. Biphasic culture strategy for enhancing volumetric  
10 erythropoietin productivity of Chinese hamster ovary cells. *Enzyme and Microbial*  
11 *Technology* 39(3):362-365.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

### Table captions

**Table 1.** Overview of heavy and light chain mRNA stability at 36.5°C and with temperature-shifted to 32°C on day 6.

**Table 2.** Average specific metabolic production and consumption rates for 36.5°C and with temperature-shifted to 32°C on day 6. Average rates were calculated from 6 sets and 3 sets of experimental data that was carried out at 36.5°C and with temperature shift, respectively. All species are shown in femtomol/cell/day except  $\mu$  which has units of 1/day. Exponential phase: days 3-6; stationary phase: days 7-10. Negative value indicates consumption. TS: Temperature shift.

### Figure legends

**Figure 1.** NSD biosynthetic pathway in mammalian cells. Raw materials that are required for NSD metabolism are sugar residues: glucose (Glc), galactose (Gal), glucosamine (GlcN), fucose (Fuc) and mannose (Man), as well as nucleotide-precursors. NSD products are transported in the ER or the Golgi for protein glycosylation. Figure modified from Murrell MP *et al.* 2004) [9].

**Figure 2.** Cell growth and specific productivity ( $q_{mAb}$ ) of secreted IgG at 36.5°C and with a temperature shift to 32°C. Viable cell concentration and cell viability profiles were measured along the period of cell culture (A), together with the  $q_{mAb}$  (B) which was calculated based on terminal secreted product, and accumulated mAb concentration profile (C) of both temperatures. Results were average measurements from 6 experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C (n=3). The error bars represent the standard deviation of the six- and triplicate samples in two cases. TS: Temperature shift.

**Figure 3.** Concentration profiles of heavy (A) and light chain (B) mRNA and H2 (C), H2L (D) intracellular assembly intermediates of IgG molecules at 36.5°C and 32°C TS. The overlay profiles of HC mRNA copy number, accumulated mAb and H<sub>2</sub> concentrations (E) suggested heavy chain to be rate determining species in mild hypothermic condition. Results were average measurements from 6 experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C TS (n=3). The error bars represent the standard deviation of the six- and triplicate samples in two cases. TS: Temperature shift.

**Figure 4.** Glycan and NSD profile of the secreted IgG. Fractions of 6 glycan structures (A): Man<sub>5</sub>, G<sub>0</sub>, G<sub>0</sub>F, G<sub>1</sub>F, G<sub>2</sub> and G<sub>2</sub>F on the secreted IgG products were determined, together with concentrations of UDP-Glc (B), UDP-GlcNAc (C) and UDP-Gal (D) that were experimentally measured. Results were average measurements from 6 experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C TS (n=3). The error bars represent the standard deviation of the six- and triplicate

1  
2  
3 samples in two cases. Statistical significance was calculated and was represented by:  $p \leq 0.05$  (\*),  
4  
5  $p \leq 0.01$  (\*\*), and  $p \leq 0.001$  (\*\*\*). TS: Temperature shift.

6  
7 **Figure 5.** Expression profile of protein N-linked glycosylation enzymes (A) and relative difference  
8  
9 in galactosyltransferase III (GalTIII) protein expression (B). Results were average measurements  
10  
11 from 6 experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C TS (n=3). The error bars  
12  
13 represent the standard deviation of the six- and triplicate samples in two cases. Statistical  
14  
15 significance was calculated and was represented by:  $p \leq 0.05$  (\*),  $p \leq 0.01$  (\*\*), and  $p \leq 0.001$  (\*\*\*). TS:  
16  
17 Temperature shift.

18  
19  
20  
21 **Figure 6.** Central carbon metabolism of CHO cells at exponential growth (days 3-6), stationary  
22  
23 phase (days 7-10) at 36.5°C and stationary phase coupled with mild hypothermia. Thickness of an  
24  
25 arrow indicates the relative flow of the carbon source within the system. This figure is simplified to  
26  
27 include carbon lost to glycerol, glycogen and lactate production, together nucleotide, NSD, lipid  
28  
29 and key amino acid synthesis.

30  
31  
32  
33 **Figure 7.** Overview of extracellular metabolite concentrations. Concentration profiles of  
34  
35 extracellular glucose (A), lactate (B) and ammonia (C) when CHO cells were culture at 36.5°C or  
36  
37 under mild hypothermia at 32°C introduced on day 6. Results were average measurements from 6  
38  
39 experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C (n=3). The error bars represent the  
40  
41 standard deviation of the six- and triplicate samples in two cases. TS: Temperature shift.

42  
43  
44 **Figure 8.** An overview of the impact of mild hypothermia on mAb glycosylation.






Figure 2. Cell growth and specific productivity ( $q_{mAb}$ ) of secreted IgG at 36.5°C and with a temperature shift to 32°C. Viable cell concentration and cell viability profiles were measured along the period of cell culture (A), together with the  $q_{mAb}$  which was calculated based on terminal secreted product, and accumulated mAb concentration profile (C) of both temperatures. Results were average measurements from 6 experimental data sets at 36.5°C ( $n=6$ ) and 3 data sets at 32°C ( $n=3$ ). The error bars represent the standard deviation of the six- and triplicate samples in two cases. TS: Temperature shift.

209x148mm (300 x 300 DPI)






Figure 3. Concentration profiles of heavy (A) and light chain (B) mRNA and H<sub>2</sub> (C), H<sub>2</sub>L (D) intracellular assembly intermediates of IgG molecules at 36.5°C and 32°C TS. The overlay profiles of HC mRNA copy number, accumulated mAb and H<sub>2</sub> concentrations (E) suggested heavy chain to be rate determining species in mild hypothermic condition. Results were average measurements from 6 experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C TS (n=3). The error bars represent the standard deviation of the six- and triplicate samples in two cases. TS: Temperature shift.

209x148mm (300 x 300 DPI)




Figure 4. Glycan and NSD profile of the secreted IgG. Fractions of 6 glycan structures (A): Man5, G0, G0F, G1F, G2 and G2F on the secreted IgG products were determined, together with concentrations of UDP-Glc (B), UDP-GlcNAc (C) and UDP-Gal (D) that were experimentally measured. Results were average measurements from 6 experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C TS (n=3). The error bars represent the standard deviation of the six- and triplicate samples in two cases. Statistical significance was calculated and was represented by:  $p \leq 0.05$  (\*),  $p \leq 0.01$  (\*\*), and  $p \leq 0.001$  (\*\*\*) . TS: Temperature shift.

209x148mm (300 x 300 DPI)




Figure 5. Expression profile of protein N-linked glycosylation enzymes (A) and relative difference in galactosyltransferase III (GalTIII) protein expression (B). Results were average measurements from 6 experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C TS (n=3). The error bars represent the standard deviation of the six- and tri-plicate samples in two cases. Statistical significance was calculated and was represented by:  $p \leq 0.05$  (\*),  $p \leq 0.01$  (\*\*), and  $p \leq 0.001$  (\*\*\*) .TS: Temperature shift.  
209x148mm (300 x 300 DPI)




Figure 6. Central carbon metabolism of CHO cells at exponential growth (days 3-6), stationary phase (days 7-10) at 36.5°C and stationary phase coupled with mild hypothermia. Thickness of an arrow indicates the relative flow of the carbon source within the system. This figure is simplified to include carbon lost to glycerol, glycogen and lactate production, together nucleotide, NSD, lipid and key amino acid synthesis. 209x148mm (300 x 300 DPI)




Figure 7. Overview of extracellular metabolite concentrations. Concentration profiles of extracellular glucose (A), lactate (B) and ammonia (C) when CHO cells were cultured at 36.5°C or under mild hypothermia at 32°C introduced on day 6. Results were average measurements from 6 experimental data sets at 36.5°C (n=6) and 3 data sets at 32°C (n=3). The error bars represent the standard deviation of the six- and triplicate samples in two cases. TS: Temperature shift.

209x148mm (300 x 300 DPI)




Figure 8. An overview of the impact of mild hypothermia on mAb glycosylation.  
209x148mm (300 x 300 DPI)

Species	Rate of decay		Units
	36.5 °C	32 °C (Day 6)	
<b>Heavy chain mRNA decay rate</b>	0.0465129 (±5.9E-005)	0.039878 (±2.3E-004)	h <sup>-1</sup>
<b>Light chain mRNA decay rate</b>	0.00588238 (±4.7E-005)	0.00459043 (±3.8E-004)	h <sup>-1</sup>

Table 1. Overview of heavy and light chain mRNA stability at 36.5°C and with temperature-shifted to 32°C on day 6.  
209x148mm (300 x 300 DPI)

	Consumption/production rate (femtomo/cell/day)			
	Exponential phase		Stationary phase	
	36.5°C	36.5°C	32°C (TS)	% difference
Ala	196.23	110.74	15.13	-631.78
Amm	-8.48	-1.65	-60.29	97.26
Arg	-38.85	-13.34	-20.95	36.33
Asn	-175.94	-50.03	-72.61	31.10
Asp	-186.85	-158.31	-122.94	-28.77
Glc	-696.02	-545.10	-268.93	-102.70
Gln	17.48	43.28	148.98	70.95
Glu	-33.50	-21.36	-11.79	-81.09
Gly	29.83	27.82	22.50	-23.65
His	-14.27	-4.17	-5.38	22.43
Ile	-53.89	-33.75	-13.28	-154.12
Lac	82.21	-109.81	-321.59	65.85
Leu	-117.92	-75.59	-33.03	-128.85
Lys	-59.59	-20.93	-36.42	42.52
Met	-15.91	-5.79	-4.87	-18.90
Phe	-26.07	-10.22	-8.45	-21.00
Pro	-43.47	-17.94	-21.26	15.62
Ser	-162.19	-58.41	-63.40	7.87
Thr	-42.47	-18.00	-11.09	-62.29
Trp	-9.17	-3.68	-2.62	-40.50
Tyr	-34.00	-12.44	-8.27	-50.46
Val	-74.57	-44.05	-26.50	-66.26
IgG	15.45	7.68	12.82	40.13
		Specific growth rate (day <sup>-1</sup> )		
$\mu$	0.30	0.02	0.00	

Table 2. Average specific metabolic production and consumption rates for 36.5°C and with temperature-shifted to 32°C on day 6. Average rates were calculated from 6 sets and 3 sets of experimental data that was carried out at 36.5°C and with temperature shift, respectively. All species are shown in femtomol/cell/day except  $\mu$  which has units of 1/day. Exponential phase: days 3-6; stationary phase: days 7-10. Negative value indicates consumption. TS: Temperature shift.  
209x148mm (300 x 300 DPI)



**Supplementary Table 1.** Forward and reverse primer pairs used in qRT-PCR experiments.

<b>Branching: N-acetylglucosaminyl Transferases (GnT)</b>		
GnT I		5'-CTGGGTGTCATGGATGACCT-3' 5'-CTAATTCCAGCTAGGATC-3'
GnT II		5'-GATGATTATAACTGGGACTGG-3' 5'-TGACTCAATTTGGGCACTCTG-3'
<b>Galactosylation: Galactosyltransferases (<math>\beta</math>-Gal T)</b>		
$\beta$ -Gal T I	AF318896	5'-GACCTGGAGCTTTTGGCAAA-3' 5'-GGGATAATGATGGCCACCTTG-3'
$\beta$ -Gal T II	AY117536	5'-CCTTCTCTGCCTGCTGCACT-3' 5'-CTGGGCTTCGGATACTGAAGC-3'
$\beta$ -Gal T III	AY117537	5'-AACTGCCATAATTGTGCCCC-3' 5'-TGCCATATGCAAGCTGCTG-3'
<b>Fucosylation</b>		
Fucosyltransferase		5'-TATGGCACCCAGCGAACACTC-3' 5'-ITCACCTGACCAGTGTCCAG-3'
<b>Nucleotide Sugar Transporters</b>		
UDP-Gal Transporter	AF299335	5'-ACACACTCAAGCTCGCGGT-3' 5'-TGTCACCTGGAAAGTGCCAG-3'
UDP-GlcNAc Transporter		5'-CAGGAGTTGCTTTTGTACAG-3' 5'-GCTGTGAGAAGTGCATGAG-3'

\*Primer sequence for the heavy and light chain can be provided upon request.

Supplementary Table 2. FBA reactions of CHO cells included in the model.

#	Reaction	Reversibility
	<b>Glycolysis</b>	
1	[c] : Glc + ATP --> G6P + ADP	Irreversible
2	[c] : G6P <=> F6P	Reversible
3	[c] : F6P + ATP --> DHAP + GAP + ADP	Irreversible
4	[c] : DHAP <=> GAP	Reversible
5	[c] : GAP + NAD + ADP <=> 3PG + NADH + ATP	Reversible
6	[c] : 3PG + ADP --> Pyr + ATP	Irreversible
	<b>TCA cycle</b>	
7	[c] : Pyr + NAD + CoASH --> AcCoA + CO <sub>2</sub> + NADH	Irreversible
8	[c] : AcCoA + Oxal --> Cit + CoASH	Irreversible
9	[c] : Cit + NADP --> αKG + CO <sub>2</sub> + NADPH	Irreversible
10	[c] : αKG + CoASH + NAD --> SucCoA + CO <sub>2</sub> + NADH	Irreversible
11	[c] : SucCoA + GDP <=> Succ + GTP + CoASH	Reversible
12	[c] : Succ + FAD <=> Fum + FADH <sub>2</sub>	Reversible
13	[c] : Fum <=> Mal	Reversible
14	[c] : Mal + NAD <=> Oxal + NADH	Reversible
	<b>Pyruvate fates</b>	
15	[c] : Pyr + NADH <=> Lac + NAD	Reversible
16	[c] : Pyr + Glu <=> Ala + αKG	Reversible
	<b>Pentose Phosphate Pathway</b>	
17	[c] : (3) G6P + (6) NADP --> (3) CO <sub>2</sub> + (3) R5P + (6) NADPH	Irreversible
	<b>Anaplerotic Reaction</b>	
18	[c] : Mal + NADP <=> Pyr + HCO <sub>3</sub> + NADPH	Reversible
	<b>Amino Acid Metabolism</b>	
19	[c] : Glu + NADP <=> αKG + NH <sub>4</sub> + NADPH	Reversible
20	[c] : Oxal + Glu <=> Asp + αKG	Reversible
21	[c] : Gln + ADP <=> Glu + ATP + NH <sub>4</sub>	Reversible
22	[c] : Thr + NAD + CoASH --> Gly + NADH + AcCoA	Irreversible
23	[c] : Ser + THF + NADP <=> Gly + NADPH + N10FTHF	Reversible
24	[c] : N10FTHF + ADP <=> ATP + Formate + THF	Reversible
25	[c] : Ser --> Pyr + NH <sub>4</sub>	Irreversible
26	[c] : Thr --> αKb + NH <sub>4</sub>	Irreversible
27	[c] : αKb + CoASH + NAD + HCO <sub>3</sub> + ATP --> SucCoA + ADP + NADH + CO <sub>2</sub>	Irreversible
28	[c] : Trp --> Ala + (2) CO <sub>2</sub> + αKa	Irreversible
29	[c] : Lys + (2) αKG + (3) NADP + FAD --> αKa + (2) Glu + (3) NADPH + FADH <sub>2</sub>	Irreversible
30	[c] : αKa + (2) CoASH + (2) NAD --> (2) AcCoA + (2) NADH + (2) CO <sub>2</sub>	Irreversible
31	[c] : Val + αKG + CoASH + NAD --> IsobutCoA + Glu + CO <sub>2</sub> + NADH	Irreversible
32	[c] : IsobutCoA + FAD + (2) NAD + HCO <sub>3</sub> + ATP --> SucCoA + ADP + FADH <sub>2</sub> + (2) NADH + CO <sub>2</sub>	Irreversible
33	[c] : IsobutCoA --> Isobut	Irreversible
34	[c] : Ile + αKG + (2) CoASH + (2) NAD + FAD + HCO <sub>3</sub> + ATP --> AcCoA + SucCoA + ADP + Glu + CO <sub>2</sub> + (2) NADH + FADH <sub>2</sub>	Irreversible
35	[c] : Leu + αKG + CoASH + NAD --> IsovalCoA + Glu + CO <sub>2</sub> + NADH	Irreversible
36	[c] : IsovalCoA + FAD + ATP + CO <sub>2</sub> + SucCoA + CoASH --> (3) AcCoA + Succ + FADH <sub>2</sub> + ADP	Irreversible
37	[c] : IsovalCoA --> Isoval	Irreversible
38	[c] : Phe + NADH --> Tyr + NAD	Irreversible
39	[c] : Tyr + αKG + SucCoA + CoASH --> Fum + (2) AcCoA + Succ + Glu + CO <sub>2</sub>	Irreversible
40	[c] : Met + Ser + ATP --> αKb + NH <sub>4</sub> + AMP	Irreversible
41	[c] : Asn <=> Asp + NH <sub>4</sub>	Reversible
42	[c] : Pro + NADP <=> Glu + NADPH	Reversible
43	[c] : Arg + αKG + NADP --> (2) Glu + NADPH + Urea	Irreversible
44	[c] : His --> Glu + NH <sub>4</sub>	Irreversible
45	[c] : Arg --> Orn + Urea	Irreversible
46	[c] : Orn --> PTRSC + CO <sub>2</sub>	Irreversible
47	[c] : Met + ATP --> SAM	Irreversible
48	[c] : SAM --> DSAM + CO <sub>2</sub>	Irreversible

49	[c] : DSAM + PTRSC --> 5MTA + SPRMD	Irreversible
50	[c] : 5MTA + SPRM --> DSAM + SPRMD	Irreversible
<b>Glycogen Synthesis</b>		
51	[c] : G6P --> G1P	Irreversible
52	[c] : G1P + UMPRN + (2) ATP --> UDPG + (2) ADP	Irreversible
53	[c] : UDPG --> Glycogen + UDP	Irreversible
<b>Nucleotide Synthesis</b>		
54	[c] : R5P + ATP --> PRPP + AMP	Irreversible
55	[c] : PRPP + (2) Gln + Gly + Asp + (5) ATP + CO <sub>2</sub> + (2) N10FTHF --> IMP + (2) Glu + Fum + (5) ADP + (2) THF	Irreversible
56	[c] : IMP + Asp + GTP --> AMPRN + Fum + GDP	Irreversible
57	[c] : IMP + Gln + ATP + NAD --> GMPRN + Glu + AMP + NADH	Irreversible
58	[c] : HCO <sub>3</sub> + NH <sub>4</sub> + Asp + (2) ATP + NAD --> Orotate + (2) ADP + NADH	Irreversible
59	[c] : Orotate + PRPP --> UMPRN + CO <sub>2</sub>	Irreversible
60	[c] : UMPRN + Gln + ATP --> CMPRN + Glu + ADP	Irreversible
61	[c] : AMPRN --> dAMP	Irreversible
62	[c] : GMPRN --> dGMP	Irreversible
63	[c] : CMPRN --> dCMP	Irreversible
64	[c] : UMPRN --> dTMP	Irreversible
<b>Lipid Synthesis</b>		
65	[c] : Choline + ATP --> Pcholine + ADP	Irreversible
66	[c] : Pcholine + (18) AcCoA + Glyc3P + (22) ATP + (33) NADH --> PC + (16) ADP + (6) AMP + (33) NAD + (18) CoASH	Irreversible
67	[c] : PC + Ser <==> PS + Choline	Reversible
68	[c] : PS --> PE + CO <sub>2</sub>	Irreversible
69	[c] : Choline + Glyc3P <==> Glyc3PC	Reversible
70	[c] : G6P --> Inositol	Irreversible
71	[c] : Inositol + (18) AcCoA + Glyc3P + (22) ATP + (33) NADH --> PI + (16) ADP + (6) AMP + (33) NAD + (18) CoASH	Irreversible
72	[c] : (18) AcCoA + (2) Glyc3P + (22) ATP + (33) NADH --> PG + (16) ADP + (6) AMP + (33) NAD + (18) CoASH	Irreversible
73	[c] : (2) PG --> DPG + Glyc	Irreversible
74	[c] : (16) AcCoA + Ser + Choline + (16) ATP + (29) NADPH --> SM + (2) CO <sub>2</sub> + (14) ADP + (2) AMP + (29) NADP + (16) CoASH	Irreversible
75	[c] : (18) AcCoA + (18) ATP + (14) NADPH --> Cholesterol + (9) CO <sub>2</sub> + (18) ADP + (14) NADP + (18) CoASH	Irreversible
<b>Biomass Formation</b>		
76	For 36.5°C [c] : (88.038) Ala + (54.1149) Arg + (54.6624) Asn + (101.835) Asp + (60.4002) Gln + (143.2041) Glu + (90.2061) Gly + (15.1986) His + (44.8731) Ile + (91.3887) Leu + (103.7403) Lys + (23.0388) Met + (41.61) Phe + (51.8592) Pro + (66.6198) Ser + (54.6843) Thr + (7.01895) Trp + (22.8855) Tyr + (65.3934) Val + (9450.507) ATP + (11.043513) AMPRN + (3.055269) Cholesterol + (8.038614) CMPRN + (3.721686) dAMP + (2.665668) dCMP + (2.79444) dGMP + (0.5913) DPG + (3.696063) dTMP + (94.6299) Glycogen + (7.437459) GMPRN + (11.622111) PC + (4.407156) PE + (0.22119) PG + (1.59651) PI + (0.438) PS + (1.382985) SM + (11.006064) UMPRN + (0.47085) NAD + (0.02847) NADP + (0.00219) FAD + (0.01095) NADH + (0.0876) NADPH + (0.001314) SucCoA + (0.01095) AcCoA + (0.012264) CoASH + (10.95) MTHF + (7.665) PTRSC + (1.533) SPRMD + (1.8615) Neu5Ac + (19.159666087446) GlcNAc + (4.43910147525) GalNAc + (14.396585756054) Mann + (6.32724069101717) Gal + (4.52592703789134) Fuc + (0) Neu5Gc --> (1) Biomass + (9450.507) ADP For 32°C TS [c] : (88.038) Ala + (54.1149) Arg + (54.6624) Asn + (101.835) Asp + (60.4002) Gln + (143.2041) Glu + (90.2061) Gly + (15.1986) His + (44.8731) Ile + (91.3887) Leu + (103.7403) Lys + (23.0388) Met + (41.61) Phe + (51.8592) Pro + (66.6198) Ser + (54.6843) Thr + (7.01895) Trp + (22.8855) Tyr + (65.3934) Val + (9450.507) ATP + (11.043513) AMPRN + (3.055269) Cholesterol + (8.038614) CMPRN + (3.721686) dAMP + (2.665668) dCMP + (2.79444) dGMP + (0.5913) DPG + (3.696063) dTMP + (94.6299) Glycogen + (7.437459) GMPRN + (11.622111) PC + (4.407156) PE + (0.22119) PG + (1.59651) PI + (0.438) PS + (1.382985) SM + (11.006064) UMPRN + (0.47085) NAD + (0.02847) NADP + (0.00219) FAD + (0.01095) NADH + (0.0876) NADPH + (0.001314) SucCoA + (0.01095) AcCoA + (0.012264) CoASH + (10.95) MTHF + (7.665) PTRSC + (1.533) SPRMD + (1.8615) Neu5Ac + (19.1750013522) GlcNAc + (4.43910147525) GalNAc + (14.38125101415) Mann + (5.40043757441596) Gal + (4.48368385448878) Fuc + (0) Neu5Gc --> (1) Biomass + (9450.507) ADP	Irreversible
<b>Other by-products</b>		
77	[c] : AcCoA + AMP <==> Acetate + CoASH + ATP	Reversible

1			
2			
3	78	[c] : DHAP + NADH <=> Glyc3P + NAD	Reversible
4	79	[c] : Glyc3P <=> Glyc	Reversible
5		<b>Glycosylation</b>	
6	80	[c] : UDPG <=> UDPGal	Reversible
7	81	[c] : Glc + ATP + GTP --> GDPMann + ADP	Irreversible
8	82	[c] : F6P + Gln + AcCoA + UTP --> UDPNAG + Glu + CoASH	Irreversible
9	83	[c] : UDPNAG + ATP + 3PG + CTP --> CMPNeu5Ac + UDP + ADP	Irreversible
10	84	[c] : GDPMann + NADPH --> GDPFuc + NADP	Irreversible
11	85	[c] : UDPNAG <=> UDP + GlcNAc	Reversible
12	86	[c] : UDPNAG <=> UDPGalNAc	Reversible
13	87	[c] : UDPGalNAc <=> GalNAc + UDP	Reversible
14	88	[c] : GDPMann <=> Mann + GDP	Reversible
15	89	[c] : UDPGal <=> Gal + UDP	Reversible
16	90	[c] : CMPNeu5Ac <=> CMP + Neu5Ac	Reversible
17	91	[c] : GDPFuc <=> GDP + Fuc	Reversible
18	92	[c] : CMPNeu5Ac <=> CMPNeu5Gc	Reversible
19	93	[c] : CMPNeu5Gc <=> CMP + Neu5Gc	Reversible
20		<b>Vitamin metabolism</b>	
21	94	[c] : Fol + NADH --> THF + NAD	Reversible
22	95	[c] : Gly + THF + NAD <=> METTHF + NH4 + CO2 + NADH	Reversible
23	96	[c] : MTHF + NADP <=> METTHF + NADPH	Reversible
24		<b>IgG Formation</b>	
25	97	[c] : (423.795512610944) Ala + (266.385750784022) Arg + (314.819523653844) Asn + (302.711080436388) Asp + (363.253296523666) Gln + (363.253296523666) Glu + (581.205274437866) Gly + (133.192875392011) His + (0) Ile + (605.422160872777) Leu + (520.663058350588) Lys + (72.6506593047332) Met + (266.385750784022) Phe + (532.771501568043) Pro + (1138.19366244082) Ser + (593.313717655321) Thr + (121.084432174555) Trp + (387.470182958577) Tyr + (690.181263394965) Val + (10.992) GDPFuc + (54.962) UDPNAG + (32.977) GDPMann + (21.985) UDPGal + (21.985) CMPNeu5Ac --> (32.977) GDP + (21.985) UDP + (21.985) CMP + (1) IgG	Irreversible
30		<b>Transport Reactions</b>	
31	98	Acetate[e] <=>	Reversible
32	99	ADP[e] <=>	Reversible
33	100	Ala[e] <=>	Reversible
34	101	AMP[e] <=>	Reversible
35	102	Arg[e] <=>	Reversible
36	103	Asn[e] <=>	Reversible
37	104	Asp[e] <=>	Reversible
38	105	ATP[e] <=>	Reversible
39	106	Biomass[e] <=>	Reversible
40	107	Choline[e] <=>	Reversible
41	108	Cit[e] <=>	Reversible
42	109	CMP[e] <=>	Reversible
43	110	CO2[e] <=>	Reversible
44	111	CoASH[e] <=>	Reversible
45	112	CTP[e] <=>	Reversible
46	113	FAD[e] <=>	Reversible
47	114	FADH2[e] <=>	Reversible
48	115	Fol[e] <=>	Reversible
49	116	Formate[e] <=>	Reversible
50	117	Fum[e] <=>	Reversible
51	118	GDP[e] <=>	Reversible
52	119	Glc[e] <=>	Reversible
53	120	Gln[e] <=>	Reversible
54	121	Glu[e] <=>	Reversible
55	122	Gly[e] <=>	Reversible
56	123	Glyc[e] <=>	Reversible
57	124	Glyc3PC[e] <=>	Reversible
58	125	GTP[e] <=>	Reversible

126	His[e] <==>	Reversible
127	IgG[e] <==>	Reversible
128	Ile[e] <==>	Reversible
129	Isobut[e] <==>	Reversible
130	Isoval[e] <==>	Reversible
131	Lac[e] <==>	Reversible
132	Leu[e] <==>	Reversible
133	Lys[e] <==>	Reversible
134	Mal[e] <==>	Reversible
135	Met[e] <==>	Reversible
136	NAD[e] <==>	Reversible
137	NADH[e] <==>	Reversible
138	NADP[e] <==>	Reversible
139	NADPH[e] <==>	Reversible
140	NH4[e] <==>	Reversible
141	Pcholine[e] <==>	Reversible
142	Phe[e] <==>	Reversible
143	Pro[e] <==>	Reversible
144	Pyr[e] <==>	Reversible
145	Ser[e] <==>	Reversible
146	SPRM[e] <==>	Reversible
147	Succ[e] <==>	Reversible
148	Thr[e] <==>	Reversible
149	Trp[e] <==>	Reversible
150	Tyr[e] <==>	Reversible
151	UDP[e] <==>	Reversible
152	Urea[e] <==>	Reversible
153	UTP[e] <==>	Reversible
154	Val[e] <==>	Reversible

**Supplementary Table 3.** FBA estimated flux values in nucleotide synthesis, lipid synthesis and protein glycosylation during stationary phase at 36.5°C and 32°C.

Reaction	Equation	Subsystem	Flux value (femtomoL/cell/day)		
			36.5°C (Day7-10)	32°C (Day7-10)	
54	[c] : R5P + ATP --> PRPP + AMP	Irreversible	Nucleotide	6.26	0.30
55	[c] : PRPP + (2) Gln + Gly + Asp + (5) ATP + CO2 + (2) N10FTHF --> IMP + (2) Glu + Fum + (5) ADP + (2) THF	Irreversible	Nucleotide	1.00	0.00
56	[c] : IMP + Asp + GTP --> AMPRN + Fum + GDP	Irreversible	Nucleotide	0.59	0.00
57	[c] : IMP + Gln + ATP + NAD --> GMPRN + Glu + AMP + NADH	Irreversible	Nucleotide	0.41	0.00
58	[c] : HCO3 + NH4 + Asp + (2) ATP + NAD --> Orotate + (2) ADP + NADH	Irreversible	Nucleotide	5.26	0.30
59	[c] : Orotate + PRPP --> UMPRN + CO2	Irreversible	Nucleotide	5.26	0.30
60	[c] : UMPRN + Gln + ATP --> CMPRN + Glu + ADP	Irreversible	Nucleotide	0.43	0.00
61	[c] : AMPRN --> dAMP	Irreversible	Nucleotide	0.15	0.00
62	[c] : GMPRN --> dGMP	Irreversible	Nucleotide	0.11	0.00
63	[c] : CMPRN --> dCMP	Irreversible	Nucleotide	0.11	0.00
64	[c] : UMPRN --> dTMP	Irreversible	Nucleotide	0.15	0.00
65	[c] : Choline + ATP --> Pcholine + ADP	Irreversible	Lipid	2.77	2.63
66	[c] : Pcholine + (18) AcCoA + Glyc3P + (22) ATP + (33) NADH --> PC + (16) ADP + (6) AMP + (33) NAD + (18) CoASH	Irreversible	Lipid	0.66	0.00
67	[c] : PC + Ser <=> PS + Choline	Reversible	Lipid	0.19	0.00
68	[c] : PS --> PE + CO2	Irreversible	Lipid	0.18	0.00
69	[c] : Choline + Glyc3P <=> Glyc3PC	Reversible	Lipid	3.53	3.53
70	[c] : G6P --> Inositol	Irreversible	Lipid	0.06	0.00
71	[c] : Inositol + (18) AcCoA + Glyc3P + (22) ATP + (33) NADH --> PI + (16) ADP + (6) AMP + (33) NAD + (18) CoASH	Irreversible	Lipid	0.06	0.00
72	[c] : (18) AcCoA + (2) Glyc3P + (22) ATP + (33) NADH --> PG + (16) ADP + (6) AMP + (33) NAD + (18) CoASH	Irreversible	Lipid	0.06	0.00
73	[c] : (2) PG --> DPG + Glyc	Irreversible	Lipid	0.02	0.00
74	[c] : (16) AcCoA + Ser + Choline + (16) ATP + (29) NADPH --> SM + (2) CO2 + (14) ADP + (2) AMP + (29) NADP + (16) CoASH	Irreversible	Lipid	0.06	0.00
75	[c] : (18) AcCoA + (18) ATP + (14) NADPH --> Cholesterol + (9) CO2 + (18) ADP + (14) NADP + (18) CoASH	Irreversible	Lipid	0.12	0.00
79	[c] : UDPG <=> UDPGal	Reversible	Glycosylation	0.46	0.30
80	[c] : Glc + ATP + GTP --> GDPMann + ADP	Irreversible	Glycosylation	1.17	0.61
81	[c] : F6P + Gln + AcCoA + UTP --> UDPNAG + Glu + CoASH	Irreversible	Glycosylation	1.53	0.76
82	[c] : UDPNAG + ATP + 3PG + CTP --> CMPNeu5Ac + UDP + ADP	Irreversible	Glycosylation	0.07	0.00
83	[c] : GDPMann + NADPH --> GDPFuc + NADP	Irreversible	Glycosylation	0.28	0.15
84	[c] : UDPNAG <=> UDP + GlcNAc	Reversible	Glycosylation	0.78	0.00
85	[c] : UDPNAG <=> UDPGalNAc	Reversible	Glycosylation	0.18	0.00
86	[c] : UDPGalNAc <=> GalNAc + UDP	Reversible	Glycosylation	0.18	0.00
87	[c] : GDPMann <=> Mann + GDP	Reversible	Glycosylation	0.58	0.00
88	[c] : UDPGal <=> Gal + UDP	Reversible	Glycosylation	0.25	0.00
89	[c] : CMPNeu5Ac <=> CMP + Neu5Ac	Reversible	Glycosylation	0.07	0.00
90	[c] : GDPFuc <=> GDP + Fuc	Reversible	Glycosylation	0.18	0.00

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review